0001209191-20-004113.txt : 20200117 0001209191-20-004113.hdr.sgml : 20200117 20200117172937 ACCESSION NUMBER: 0001209191-20-004113 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200115 FILED AS OF DATE: 20200117 DATE AS OF CHANGE: 20200117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ROBINS HARLAN S CENTRAL INDEX KEY: 0001780851 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 20534482 MAIL ADDRESS: STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION STREET 2: 1551 EASTLAKE AVE E STE 200 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-15 0 0001478320 Adaptive Biotechnologies Corp ADPT 0001780851 ROBINS HARLAN S C/O ADAPTIVE BIOTECHNOLOGIES CORP. SUITE 200 SEATTLE WA 98102 0 1 0 0 Chief Scientific Officer Common Stock 2020-01-15 4 M 0 3700 6.32 A 74379 D Common Stock 2020-01-15 4 S 0 3700 29.52 D 70679 D Common Stock 2020-01-16 4 M 0 3700 6.32 A 74379 D Common Stock 2020-01-16 4 S 0 1100 27.80 D 73279 D Common Stock 2020-01-16 4 S 0 1300 28.98 D 71979 D Common Stock 2020-01-16 4 S 0 1300 29.54 D 70679 D Common Stock 2020-01-17 4 M 0 3700 6.32 A 74379 D Common Stock 2020-01-17 4 S 0 1300 27.33 D 73079 D Common Stock 2020-01-17 4 S 0 2400 28.30 D 70679 D Common Stock 300000 I By CMR 2014 Brother's Trust U/T/A dated July 2, 2014 Common Stock 500000 I By CMR 2014 Mother's Trust U/T/A dated July 2, 2014 Stock Option (Right to Buy) 6.32 2020-01-15 4 M 0 3700 0.00 D 2025-06-09 Common Stock 3700 596300 D Stock Option (Right to Buy) 6.32 2020-01-16 4 M 0 3700 0.00 D 2025-06-09 Common Stock 3700 592600 D Stock Option (Right to Buy) 6.32 2020-01-17 4 M 0 3700 0.00 D 2025-06-09 Common Stock 3700 588900 D These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $29.25 to 29.74, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $27.39 to 28.31, inclusive. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $28.40 to 29.39, inclusive. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $29.40 to 29.69, inclusive. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $27.11 to 27.89, inclusive. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $28.09 to 28.66, inclusive. The option is fully vested and exercisable. /s/ Harlan Robins by Eric Billings, Attorney-in-Fact 2020-01-17 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT

ADAPTIVE BIOTECHNOLOGIES CORPORATION

LIMITED POWER OF ATTORNEY
FOR SECTION 16(a) REPORTING

	KNOW ALL PERSONS BY THESE PRESENTS, that, in addition to the appointees
designated as having powers of attorney regarding reporting requirements under
Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange
Act") with respect to equity securities of the Company, we hereby make,
constitute and appoint Eric Billings as the undersigned's true and lawful
attorney-in-fact (the "Attorney-in-Fact"), with full power of substitution and
resubstitution, each with the power to act alone for the undersigned and in the
undersigned's name, place and stead, in any and all capacities to:

	1.	Prepare, execute, deliver and file with the United States Securities and
Exchange Commission, any national securities exchange and Adaptive
Biotechnologies Corporation (the "Company") any and all reports (including any
amendment thereto) of the undersigned required or considered advisable under
Section 16(a) of the Exchange Act, and the rules and regulations thereunder,
with respect to the equity securities of the Company, including Form 3 (Initial
Statement of Beneficial Ownership of Securities), Form 4 (Statement of Changes
in Beneficial Ownership), and Form 5 (Annual Statement of Changes in Beneficial
Ownership); and
	2.	Seek or obtain, as the undersigned's representative and on the undersigned's
behalf, information on transactions in the Company's equity securities from any
third party, including the Company, brokers, dealers, employee benefit plan
administrators and trustees, and the undersigned hereby authorizes any such
third party to release any such information to the Attorney-in-Fact.

	The undersigned acknowledges that:

	1.	This Limited Power of Attorney authorizes, but does not require, the
Attorney-in-Fact to act at his or her discretion on information provided to such
Attorney-in-Fact without independent verification of such information;
	2.	Any documents prepared and/or executed by the Attorney-in-Fact on behalf of
the undersigned pursuant to this Limited Power of Attorney will be in such form
and will contain such information as the Attorney-in-Fact, in his or her
discretion, deems necessary or desirable;
	3.	Neither the Company nor the Attorney-in-Fact assumes any liability for the
undersigned's responsibility to comply with the requirements of Section 16 of
the Exchange Act, any liability of the undersigned for any failure to comply
with such requirements, or any liability of the undersigned for disgorgement of
profits under Section 16(b) of the Exchange Act; and
	4.	This Limited Power of Attorney does not relieve the undersigned from
responsibility for compliance with the undersigned's obligations under Section
16 of the Exchange Act, including, without, limitation, the reporting
requirements under Section 16(a) of the Exchange Act.

	The undersigned hereby grants to the Attorney-in-Fact full power and authority
to do and perform each and every act and thing requisite, necessary or
convenient to be done in connection with the foregoing, as fully, to all intents
and purposes, as the undersigned might or could do in person, hereby ratifying
and confirming all that the Attorney-in-Fact, or his or her substitute or
substitutes, shall lawfully do or cause to be done by authority of this Limited
Power of Attorney.

	This Limited Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 or 5 with respect to the
undersigned's holdings of and transactions in equity securities of the Company,
and shall only be revoked upon the earliest of (i) revocation by the undersigned
in a signed writing delivered to the Attorney-in-Fact or to the Secretary of the
Company, (ii) termination of the undersigned's service as an employee or
director (as applicable) of the Company, (iii) termination of the
Attorney-in-Fact's service as an officer or other employee of the Company, or
(iv) execution of a subsequent power of attorney by the undersigned which
specifically provides for the revocation of any prior power of attorney
regarding reporting requirements under Section 16(a) of the Exchange Act .

	This Limited Power of Attorney shall be governed and construed in accordance
the laws of the State of Washington without regard to the laws that might
otherwise govern under applicable principles of conflicts of laws thereof.

	IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney
to be executed as of September 26, 2019.

	Signature: /s/ Harlan Robins
	Name: Harlan Robins